Sickle Cell Disease Treatment Demonstration Program (SCDTDP)

Sickle Cell Disease Treatment Demonstration Program (SCDTDP) is sponsored by Health Resources and Services Administration (HRSA). The SCDTDP aims to expand access to high-quality, coordinated, and comprehensive care for people living with sickle cell disease.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES # Maternal and Child Health Bureau # Division of Services for Children with Special Health Needs # Sickle Cell Disease Treatment Demonstration Program # Funding Opportunity Number: HRSA-21-032 # Funding Opportunity Type(s): New, Competing Continuation # Assistance Listings (CFDA) Number: 93. 365 # NOTICE OF FUNDING OPPORTUNITY # Application Due Date: May 3, 2021 Ensure your SAM.

gov and Grants. gov registrations and passwords are current immediately! HRSA will not approve deadline extensions for lack of registration.

Registration in all systems, including SAM. gov and Grants. gov, may take up to 1 month to complete.

Issuance Date: February 23, 2021 Branch Chief, Genetic Services Branch Telephone: (301) 945-4817 Authority: 42 USC § 300b-5(b) (§1106(b) of the Public Health Service Act) HRSA-21-032 i The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2021 for the Sickle Cell Disease Treatment Demonstration Program (TDP).

The purpose of the TDP is to increase access to quality, coordinated, comprehensive care for individuals with sickle cell disease by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with sickle cell disease, and 3) improving care coordination with other providers.

Funding Opportunity Title: Sickle Cell Disease Treatment Demonstration Program Funding Opportunity Number: HRSA-21-032 Due Date for Applications: May 3, 2021 Anticipated Total Annual Available Estimated Number and Type of Award(s): Up to five cooperative agreement(s) Estimated Award Amount: Per year: Heartland and Southwest - $900,000 Subject to the availability of appropriated funds.

Cost Sharing/Match Required: No Period of Performance: September 1, 2021 through Eligible Applicants: A federally qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and has at least 5 years of experience in working with individuals who have sickle cell disease.

See Section III. 1 of this notice of funding opportunity (NOFO) for complete eligibility information. HRSA-21-032 ii You (the applicant organization/agency) are responsible for reading and complying with the instructions included in HRSA’s SF-424 Application Guide, available online at http://www.

hrsa. gov/grants/apply/applicationguide/sf424guide. pdf , except where instructed in this NOFO to do otherwise.

HRSA has scheduled the following technical assistance: Day and Date: Friday, March 19, 2021 Call-In Number: 1-866-505-4412 Participant Code: 88987753 Weblink: https://hrsa. connectsolutions. com/hrsa21032/ HRSA will record the webinar and make it available at: https://mchb.

hrsa. gov/fundingopportunities/default. aspx .

HRSA-21-032 iii I. PROGRAM FUNDING OPPORTUNITY DESCRIPTION ................................ ......................

1 1. PURPOSE ................................................................................................ ......................

1 2. BACKGROUND ................................................................................................ ................

3 II. AWARD INFORMATION ................................................................................................ ....

4 1. TYPE OF APPLICATION AND AWARD ................................................................ .................

4 2. SUMMARY OF F UNDING ................................................................................................ ...

6 III. ELIGIBILITY INFORMATION ................................................................ ............................

6 1. ELIGIBL E APPLICANTS ................................................................................................ ....

6 2. COST S HARING /M ATCHING ................................................................ ..............................

6 3. O THER ................................................................................................ ..........................

6 IV. APPLICATION AND SUBMISSION INFORMATION ................................ .........................

7 1. ADDRESS T O R EQUEST APPLICATION PACKAGE ................................ ...............................

7 2. CONT ENT AND F ORM OF APPLICATION S UBMISSION ................................ ..........................

7 i. Project Abstract ................................................................................................. 10 ii.

Project Narrative ................................................................................................ 10 iii. Budget ...............................................................................................................

13 iv. Budget Narrative ............................................................................................... 14 v.

Program-Specific Forms ................................................................................... 15 vi. Attachments ......................................................................................................

15 3. DUN AND BRADSTREET DATA UNIVERSAL NUMBERING SYSTEM (DUNS) NUMBER TRANSITION TO T HE U NIQUE E NTIT Y I DENTIFIER (UEI) AND S YST EM FOR AWARD M ANAGEM ENT (SAM) ..... 16 4.

SUBMISSION DAT ES AND TIM ES ..................................................................................... 17 5. I NT ERGOV ERNM ENTAL R EVIEW ......................................................................................

17 6. F UNDING R EST RICTIONS ............................................................................................... 17 V.

APPLICATION REVIEW INFORMATION......................................................................... 18 1. REVIEW C RIT ERIA .........................................................................................................

18 2. REVIEW AND S EL ECTION P ROCESS ................................................................................ 20 3.

ASSESSM ENT OF RISK .................................................................................................. 20 VI. AWARD ADMINISTRATION INFORMATION..................................................................

21 1. AWARD N OTICES .......................................................................................................... 21 2.

ADMINIST RATIV E AND NATIONAL P OLICY R EQUIREM ENTS ................................................ 21 3. REPORTING .................................................................................................................

22 VII. AGENCY CONTACTS ................................................................................................... 24 VIII.

OTHER INFORMATION................................................................................................ 25 HRSA-21-032 1 # I. Program Funding Opportunity Description This notice announces the opportunity to apply for funding under the Sickle Cell Disease Treatment Demonstration Program (TDP).

The purpose of the TDP is to increase access for individuals with sickle cell disease (SCD) to quality, coordinated, comprehensive care by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with SCD, and 3) improving care coordination with other providers.

HRSA funds a portfolio of three coordinated programs to improve outcomes of individuals with SCD and their families: the Sickle Cell Disease Newborn Screening Follow-up Program (HRSA-21-036), the Sickle Cell Disease Treatment Demonstration Program (HRSA-21-032), and the Hemoglobinopathies National Coordinating Center (funded by a contract).

Together the programs strengthen the sickle cell disease system of care and support by: 1) educating patients, families and clinicians to improve knowledge and capacities; 2) linking individuals and families to evidence-based care; and 3) fostering partnerships between clinicians, community organizations and other stakeholders to improve the ability to deliver coordinated, comprehensive care across the lifespan.

The goal of the TDP is to improve outcomes of individuals with SCD and their families by developing and supporting a regional SCD infrastructure that includes components necessary for providing comprehensive services to individuals with SCD and their families.

The successful recipient must collaborate with clinics/practices in at least seven (7) states within a single region in order to: develop and support comprehensive SCD care teams 1; implementation of telehealth technologies for health care delivery, education and health information services 2; increased access to evidence-based care and the latest treatment options; and increased collaboration and care coordination within each region.

One award will be made to a recipient providing such development and support in each of the five regions listed below, which have been programmatically designated as HRSA Sickle Cell Disease Regions. 1. Northeast: Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont, District of Columbia, Delaware, Maryland, New York, New Jersey, Pennsylvania, Virginia, West Virginia, Virgin Islands and Puerto Rico 2.

Southeast: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee > 1Kanter J, Smith WR, Desai PC, et al. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv.

2020;4(16):3804-3813. > 2Telehealth is defined as the use of electronic information and telecommunication technologies to support long-distance clinical health care, patient and professional health-related education, public health, and health administration. Technologies include video conferencing, the internet, store-and-forward imaging, streaming media, and terrestrial and wireless communications.

https://www. hrsa. gov/rural-health/telehealth 3.

Midwest: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin, North Dakota, and South Dakota 4. Heartland and Southwest: Iowa, Missouri, Arkansas, Louisiana, Nebraska, Kansas, Oklahoma, and Texas 5.

Pacific: New Mexico, Montana, Utah, Wyoming, Colorado, Alaska, Arizona, California, Hawaii, Idaho, Nevada, Oregon, and Washington Per year, the recipient providing support to each region specified below will receive the following specified amounts: Heartland and Southwest $900,000 In addition, recipients of the TDP will work with the recipients of the Sickle Cell Disease Newborn Screening Follow-up Program (HRSA-21-036) and the Hemoglobinopathies National Coordinating Center to create synergies of efforts, reduce duplication and develop a Report to Congress.

Each awardee will report annually on the following Program Objectives: • By August 2022, establish a partnership (e.g., Memorandum of Understanding (MOU) or shared work plan) with the recipients of the Sickle Cell Disease Newborn Screening Follow-up Program (HRSA-21-036) within your region to develop an action plan to make services accessible to all individuals and families living with SCD within the region.

Examples of activities that might be addressed by the plan include collaborating on: o Linking families to specialty SCD care; o Using telehealth to link individuals and families with education and support Identifying community-based services in the state and region; o Providing education, support, or disseminating resources through multiple vehicles; and/or o Linking to the state newborn screening program and/or the state Maternal and Child Health Services Block Grant Program.

• By August 2024, update the action plan described above. • By August 2023, partner with organizations within at least seven states in your region to develop and implement a Sickle Cell Disease Regional/Organizational Action Plan to increase access to evidence-based care and treatments for individuals with sickle cell disease.

3 • By August 2026, increase by 25 percent from baseline, the total number of providers 4 in your region that are delivering evidence-based sickle cell disease care to patients as part of comprehensive care teams. > 3Recipients are expected to submit action plans in Year 2 and update the action plans in Year 4 of the project.

> 4Providers may include hematologists, primary care physicians, advanced practice providers, social workers, nurse practitioners, behavioral health specialists and others. • By August 2026, increase by 30 percent from baseline, the total number of individuals in your region receiving disease modifying therapies.

• By August 2026, increase by 25 percent from baseline, the number of patients receiving SCD care through telemedicine in your region. Baseline data will be collected by March 2022. The regions will be expected to provide data annually (overall and by state) on how they are achieving the goals and objectives of the program.

This program is authorized 42 USC 300b-5(b) (Public Health Service Act, Section 1106(b)). as added by the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018 (P. L.

115-327). Sickle cell disease (SCD) is the most common inherited blood disorder in the United States (U.S.), affecting an estimated 100,000 individuals. This lifelong condition disproportionately affects Black (1 of every 365 births) and Hispanic Americans (1 of every 16,300 births 5 with cases also occurring in individuals of Mediterranean, Middle Eastern and Asian descent.

SCD causes the body to produce abnormal red blood cells that break forming a sickle shape impeding blood flow and causing anemia, severe pain, organ damage and other complications including reduced life expectancy. Early entry into evidence-based care improves health outcomes.

Over the past 40 years, life expectancy for individuals with SCD has increased significantly due to advances in evidence-based care 6, including the availability of three U.S. Food and Drug Administration approved medications including hydroxyurea, crizanlizumab-tmca, and voxelotor. While newborn screening for SCD occurs in every state, there are still barriers to accessing comprehensive, high-quality care throughout the lifespan.

7 Many individuals with SCD experience poor health outcomes resulting from barriers to accessing evidence-based care, new medications and therapies, education, care coordination, and other supports. Many individuals and families live far from SCD specialists and disproportionately access care through the emergency department.

8 During transition from the pediatric to adult health care system young adults frequently, experience an increase in adverse health events including premature death. 9 In addition, discrimination and social determinants 10 of health negatively affect the health of individuals with SCD. 8 > 5Data and Statistics on Sickle Cell Disease .

(2019). Centers for Disease Control and Prevention, Atlanta, GA. > 6https://www.

nhlbi. nih. gov/health-topics/evidence-based-management-sickle-cell-disease > 7Minkovitz CS, Grason H, Ruderman M, Casella JF.

Newborn Screening Programs and Sickle Cell Disease: A Public Health Services and Systems Approach. Am J Prev Med. 2016;51(1 Suppl 1):S39-S47.

> 8Mathur VA et al. Multiple levels of suffering: Discrimination in health-care settings is associated with enhanced laboratory pain sensitivity in sickle cell disease. Clin J Pain; 2016; 32:1076–1085.

> 9Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci.

2018;2(5):334-342. > 10 What are social determinants of health? (2020).

Centers for Disease Control and Prevention, Atlanta, GA. Due to these challenges, there remains a critical need for comprehensive care for individuals with SCD. Comprehensive care must include a multidisciplinary, team-based approach that includes timely access to services.

Models of care for SCD can vary from having dedicated, trained hematologists providing services (usually in an urban area) to extending the reach of hematologists via telehealth where care can be provided by a trained primary care provider. 11 In September 2020, the National Academies of Sciences, Engineering, and Medicine released a report that included a blueprint and strategies to improve care for individuals with SCD.

The report described the importance of collecting data to measure burden of disease, outcomes and needs of individuals with SCD; the need for organized systems of care to meet both clinical and social needs of individuals with SCD; and increase the number of qualified clinicians providing SCD care. 12 HRSA has funded the TDP since 2005 under section 712(c) of the American Jobs Creation Act of 2004, P. L.

108-357, which authorized the TDP to improve the prevention and treatment of sickle cell disease, including by patient and provider education and coordinating service delivery for individuals with sickle cell disease.

In this cycle, the TDP will build on previous funding cycles and advances in the field and support Healthy People 2030 SCD objective BDBS-2030-02 13 by focusing on: building and supporting comprehensive sickle cell care teams; implementing telemedicine to reach individuals with sickle cell in rural areas; conducting Project ECHO 14 sessions to educate and train providers; increasing collaboration with the Sickle Cell Disease Newborn Screening and Follow-up program (HRSA-21-036) to strengthen patient and family engagement and increase educational opportunities for providers; and collaborating with the Hemoglobinopathies National Coordinating Center (HNCC) on data collection, developing a Report to Congress, and conducting quality improvement activities.

1. Type of Application and Award Type(s) of applications sought: New and Competing Continuation. HRSA will provide funding in the form of a cooperative agreement.

A cooperative agreement is a financial assistance mechanism where HRSA anticipates substantial involvement with the recipient during performance of the contemplated project. HRSA program involvement will include : • Participating and collaborating in the planning, implementation, and evaluation of program activities under this cooperative agreement. > 11 Kanter J, Smith WR, Desai PC, et al.

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020;4(16):3804-3813.

> 13 https://www. healthypeople. gov/sites/default/files/ObjectivesPublicComment508.

pdf > 14 Project ECHO stands for Extension for Community Healthcare Outcomes and uses telehealth technology to train providers using practice-based learning. See https://hsc. unm.

edu/echo/ for more information. • Assessing and evaluating to determine program needs to meet the scope of work described in the NOFO on an ongoing basis. • Reviewing information on project activities, reports, and any other product prior to dissemination as well as providing review of and advisory input for publications, audiovisuals, and other materials produced under the auspices of this cooperative agreement.

• Participating in the planning and scheduling of meetings and attending Project ECHO sessions (when appropriate) conducted during the period of the cooperative agreement. • Participating in regular meetings and/or communications with the recipient to assess progress (at minimum monthly check-ins).

• Assisting the recipient in identifying and facilitating linkages with federal interagency and state contacts as necessary for the successful completion of tasks and activities identified in the approved scope of work. • Participating in the design, direction, and evaluation of innovative activities. • Facilitating efforts in the logistics related to the provision of technical support and training/education when needed.

The cooperative agreement recipient’s responsibilities will include: • Adhering to the process of planning, implementing, and evaluating program activities as outlined in this NOFO. • Establishing monthly check-ins with HRSA Program staff, with increased frequency of meetings as needed. • Responding in a timely and appropriate manner to requests by the HRSA project officer to collaborate on short-term, long-term and ongoing projects.

• Assuring sufficient staff to manage the expectations of this NOFO. • Seeking HRSA project officer input prior to selecting and hiring new key project staff. • Working closely with the HRSA project officer when developing, planning, and implementing new activities.

• Consulting with the HRSA project officer when scheduling any meetings that pertain to the scope of work and at which the HRSA project officer’s attendance would be appropriate (as determined by the project officer).

• Providing the HRSA project officer with adequate time and opportunity to review, provide advisory input, and approve at the program level, any publications, audiovisuals, and other materials produced under the auspices of this cooperative agreement (such review should start as part of concept development and include review of drafts and final products).

• Providing the HRSA project officer with an electronic copy of, or electronic access to, each product developed under the auspices of this project. • Ensuring that all products developed or produced, either partially or in full, under the auspices of this cooperative agreement are fully accessible and available for free to members of the public.

• Acknowledgement that the federal government, including HRSA/MCHB, has a royalty-free, nonexclusive, and irrevocable license to reproduce, publish, or otherwise use any products derived from activities conducted under this cooperative agreement. • Collaborating and communicating with the HRSA Program staff and other key stakeholders. HRSA-21-032 6 • Participating in all HNCC led activities and workgroups.

• Supporting all related activities outlined in this NOFO. HRSA estimates approximately $5,000,000 to be available annually to fund five (5) recipients. You may apply for a ceiling amount predetermined for each region and the total cost includes both direct and indirect, facilities and administrative costs per year.

Use the table below to determine the amount of funding you are allowed to apply for in your region: Heartland and Southwest $900,000 The period of performance is September 1, 2021 through August 31, 2026 (5 years).

Funding beyond the first year is subject to the availability of appropriated funds for the Sickle Cell Disease Treatment Demonstration Program in subsequent fiscal years, satisfactory recipient performance, and a decision that continued funding is in the best interest of the Federal Government. All HRSA awards are subject to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements at 45 CFR part 75 . # III.

Eligibility Information Eligible applicants include a Federally-qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and demonstrates to the HRSA Administrator that either the federally-qualified health center, the nonprofit hospital or clinic, the university health center, the organization or entity described in clause (i) 42 USC § 300b-5, or experts as described in paragraph (2)(C) of 42 USC § 300b-5, has at least five (5) years of experience in working with individuals who have sickle cell disease.

Federally-qualified health center is defined in section 1905(l)(2)(B) of the Social Security Act ( 42 U.S.C. 1396d(l)(2)(B) ). Cost sharing/matching is not required for this program.

HRSA will consider any application that exceeds the ceiling amount non-responsive and will not consider it for funding under this notice. HRSA will consider any application that fails to satisfy the deadline requirements referenced in Section IV. 4 non-responsive and will not consider it for funding under this notice.

NOTE: Multiple applications from an organization are not allowable. HRSA will only accept your last validated electronic submission, under the correct funding opportunity number, prior to the Grants. gov application due date as the final and only acceptable application.

# IV. Application and Submission Information 1. Address to Request Application Package HRSA requires you to apply electronically.

HRSA encourages you to apply through Grants. gov using the SF-424 workspace application package associated with this notice of funding opportunity (NOFO) following the directions provided at http://www. grants.

gov/applicants/apply-for-grants. html . 2.

Content and Form of Application Submission Section 4 of HRSA’s SF-424 Application Guide provides instructions for the budget, budget narrative, staffing plan and personnel requirements, assurances, certifications, and abstract. You must submit the information outlined in the Application Guide in addition to the program-specific information below.

You are responsible for reading and complying with the instructions included in HRSA’s SF-424 Application Guide except where instructed in the NOFO to do otherwise. You must submit the application in the English language and in the terms of U.S. dollars (45 CFR § 75. 111(a)).

See Section 8. 5 of the Application Guide for the Application Completeness Checklist. The total size of all uploaded files included in the page limit may not exceed the equivalent of 80 pages when printed by HRSA.

The page limit includes the abstract, project and budget narratives, attachments, and letters of commitment and support required in the Application Guide and this NOFO. Standard OMB-approved forms that are included in the workspace application package do not count in the page limit.

HRSA-21-032 8 Please note: If you use an OMB-approved form that is not included in the workspace application package for HRSA-21-032, it may count against the page limit. Therefore, we strongly recommend you only use Grants. gov workspace forms associated with this NOFO to avoid exceeding the page limit.

Indirect Cost Rate Agreement and proof of non-profit status (if applicable) do not count in the page limit. It is therefore important to take appropriate measures to ensure your application does not exceed the specified page limit. Any application exceeding the page limit of 80 will not be read, evaluated or considered for funding.

Applications must be complete, within the maximum specified page limit, and validated by Grants. gov under the correct funding opportunity number prior to the deadline.

Debarment, Suspension, Ineligibility, and Voluntary Exclusion Certification 1) You certify on behalf of the applicant organization, by submission of your proposal, that neither you nor your principals are presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any federal department or agency.

2) Failure to make required disclosures can result in any of the remedies described in 45 CFR § 75. 371, including suspension or debarment. (See also 2 CFR parts 180 and 376, and 31 U.S.C.

§ 3321). 3) Where you are unable to attest to the statements in this certification, an explanation shall be included in Attachment 9: Other Relevant Documents . See Section 4.

1 viii of HRSA’s SF-424 Application Guide for additional information on all certifications. Section 319(e) of the Public Health Service (PHS) Act provides the Secretary of the Department of Health and Human Services (HHS) with discretion upon request by a state or tribal organization to authorize the temporary reassignment of state, tribal, and local personnel during a declared federal public health emergency.

The temporary reassignment provision is applicable to state, tribal, and local public health department or agency personnel whose positions are funded, in full or part, under PHS programs and allows such personnel to immediately respond to the public health emergency in the affected jurisdiction. Funds provided under the award may be used to support personnel who are temporarily reassigned in accordance with § 319(e).

Please reference detailed information available on the HHS Office of the Assistant Secretary for Preparedness (ASPR) website via http://www. phe. gov/Preparedness/legal/pahpa/section201/Pages/default.

aspx . Program-Specific Instructions In addition to application requirements and instructions in Section 4 of HRSA’s SF-424 Application Guide (including the budget, budget narrative, staffing plan and personnel requirements, assurances, certifications, and abstract), ensure details related to the following activities are included: Infrastructure and Capacity Building • Develop and support regional and state SCD network infrastructure.

HRSA-21-032 9 • Develop and implement Regional/State/Organizational Action Plans and update at least once every 2 years. • Collaborate with organizations in at least seven (7) states within the region to address SCD treatment and services. • Establish partnerships and/or contracts as appropriate with academic institutions, health systems, public health entities, etc., to coordinate access to services.

• Establish SCD care teams within the region in order to provide comprehensive services to individuals with SCD. • Engage individuals and families living with SCD in all aspects of the project including planning, implementation and monitoring. • Implement telehealth to provide evidence-based care to individuals with SCD especially those who live in rural areas.

Collaboration and Partnerships • Collaborate with recipients of the Sickle Cell Disease Newborn Screening Follow-up Program (HRSA-21-036) to develop, implement, and update an action plan to make community based services accessible to all individuals and families living with SCD within the state.

o Establish Memoranda of Understanding/Memoranda of Agreement with recipients funded by the Sickle Cell Disease Newborn Screening Follow-up program (HRSA-21-036). o Collaborate and coordinate with HRSA-21-036 funding recipients on patient service referrals, and patient, health professional, and community education.

• Participate in HNCC activities including: o Serving on the National SCD Steering Committee (Steering Committee) and Regional Workgroups to develop and implement strategies that improve access to evidence-based SCD care nationally and within participating states/regions.

Steering Committee/Workgroup activities will address priorities identified in the TDP Action Plans and other emerging needs at the national, regional, and state levels.

o Participating in the HNCC-led quality improvement activities to identify best and promising practices and innovative strategies on topics including:  Current therapies and treatments, including hydroxyurea  Transition from pediatric to adult care  Prevention of SCD complications  Providing comprehensive, wrap-around services o Collaborating with the HNCC to evaluate program activities, including collecting regional data, aggregated data on objectives and performance measures, and submitting all data to the HNCC.

o Partnering with the HNCC to develop a Report to Congress, Model Protocol and Compendium of Resources. o Attending annual grantee meetings hosted by the HNCC. HRSA-21-032 10 • Collaborate with the American Society for Hematology, Pediatric Emergency Care Applied Research Network, and Patient-Centered Outcomes Research Institute in order to align quality improvement activities.

• Establish and support Project ECHO sessions to educate and train providers on evidence-based care and the latest disease-modifying therapies. • Develop and widely disseminate provider educational tools and materials describing evidence-based guidelines in coordination with the HNCC.

• Develop educational resources (e.g., tools, toolkits, webinars, fact sheets, issues briefs, and other publications) for providers that make up a SCD care team to increase their ability to provide comprehensive services. • Establish communication strategies to share information, successes, and barriers throughout the region. • Convene an annual regional meeting of CBOs, partners, stakeholders, and SCD experts within the region.

See Section 4. 1. ix of HRSA’s SF-424 Application Guide .

This section provides a comprehensive framework and description of all aspects of the proposed project. It should be succinct, self-explanatory, consistent with forms and attachments, and well-organized so that reviewers can understand the proposed project. Successful applications will contain the information below.

Please use the following section headers for the narrative:  INTRODUCTION -- Corresponds to Section V’s Review Criterion 1 Need Briefly describe the purpose of the proposed project.  NEEDS ASSESSMENT -- Corresponds to Section V’s Review Criterion 1 Need Outline the needs of individuals living with SCD in your region. Describe and document the target communities and/or populations and its unmet health needs.

Provide an estimate of the SCD prevalence in your region. Use and cite demographic data whenever possible to support the information provided. Discuss any relevant barriers in the service area that the project hopes to overcome.

This section will help reviewers understand the communities/populations that you will serve with the proposed project.  METHODOLOGY -- Corresponds to Section V’s Review Criterion 2 Response Propose methods that you will use to address the stated needs and meet each of the previously described program requirements and expectations in this NOFO under Purpose and Program-Specific Instructions .

As appropriate, include development of effective tools and strategies for ongoing staff training, outreach, collaborations, clear communication, and information sharing/dissemination with efforts to involve patients, families, and communities. If applicable, include a plan to disseminate reports, products, and/or project outputs so key target audiences receive the project information.

HRSA-21-032 11 Describe a plan to support a regional infrastructure of comprehensive SCD services. Provide an overview of how you will collaborate with organizations in at least seven (7) states within the region to address SCD treatment and services.

Describe how you will establish partnerships and/or contracts as appropriate with academic institutions, health systems, public health entities, etc. to coordinate access to services and comprehensive care teams.

Describe how you will collaborate with recipients of the Sickle Cell Disease Newborn Screening Follow-up program (HRSA-21-036) and develop and implement a plan to make CBOs services accessible to all individuals and families living with SCD within the state. In addition, describe a plan that trains providers in order to create a SCD care team that provides comprehensive services.

Describe how health care providers such as hematologists, primary care providers, advanced practice providers, and other service providers will be recruited to participate in comprehensive SCD care teams. Include a description of any innovative methods that you will use to address the stated needs. Propose a plan for project sustainability after the period of federal funding ends.

HRSA expects recipients to sustain key elements of their projects, e.g., strategies or services and interventions, which have been effective in improving practices and those that have led to improved outcomes for the target population.

 WORK PLAN -- Corresponds to Section V’s Review Criteria 2 Response and 4 Describe the activities or steps that you will use to achieve each of the objectives proposed during the entire period of performance in the Methodology section. Use a time line that includes each activity and identifies responsible staff.

As appropriate, identify meaningful support and collaboration with key stakeholders in planning, designing, and implementing all activities, including developing the application. Submit a logic model for designing and managing the project. A logic model is a one-page diagram that presents the conceptual framework for a proposed project and explains the links among program elements.

While there are many versions of logic models, for the purposes of this notice, the logic model should summarize the connections between the: Goals of the project (e.g., reasons for proposing the intervention, if applicable); Assumptions (e.g., beliefs about how the program will work and support resources. Base assumptions on research, best practices, and experience.)

; Inputs (e.g., organizational profile, collaborative partners, key personnel, HRSA-21-032 12